Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, Sang‐Soo Lee, Chiranjib Chakraborty
Abstract
The world has faced 3 years of the COVID-19 pandemic with billions of infections, millions of deaths, and a massive economic crisis. Since the pandemic began, scientists have started to fight against SARS-CoV-2. One significant scientific effort was searching for successful therapeutic molecules against the virus. The repurposing of the drug candidates was initiated in the initial stage of the pandemic.1,2,3 Along with drug repurposing, new molecule discovery was started by exploring the drug targets.
Topics & Concepts
RepurposingDrug repositioningScopusCoronavirus disease 2019 (COVID-19)PandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PharmacologyMedicineTraditional medicineDrugMEDLINEBiologyInternal medicineInfectious disease (medical specialty)BiochemistryDiseaseEcologySARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery MethodsCOVID-19 Clinical Research Studies